FDA's “All-in” Approach to Enterprise Transformation
By Janet Woodcock & Meredith Chuk
Fulfilling Essential Public Health Needs in 2022
By Janet Woodcock
MAQC and the era of genomic medicine
By Marc L. Salit & Janet Woodcock
New Era of Smarter Food Safety Blueprint Makes Inroads
By Janet Woodcock & Frank Yiannas
FDA's Budget: Data Modernization and Enhanced Technologies
By Janet Woodcock
FDA's Budget: Advancing the Goal of Ending the Opioid Crisis
By Janet Woodcock
Trends in COVID-19 therapeutic clinical trials
By Janet Woodcock & Kevin Bugin
FDA career officials: We're committed to science-based health decisions
By Susan Mayne, Janet Woodcock & Mitch Zeller
FDA Announces Latest Step Toward Finalizing Memorandum of Understanding with States Addressing Compounded ...
By Janet Woodcock
Quality: The Often Overlooked Critical Element For Assuring Access To Safe And Effective Drugs
By Janet Woodcock & Michael Kopcha
Safety, Efficacy, and Quality Remain Top Priorities as We Continue Our Work to Expand Access to Cost-Saving Generic ...
By Janet Woodcock
2018: A Year of Innovation, Efficiency, and New Advances in Drug Therapy for the American Public
By Janet Woodcock
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
By H. Hampel, Stefan J. Teipel & Kaj Blennow
The US regulatory and pharmacopeia response to the global heparin contamination crisis
By Robert J. Linhardt, Janet Woodcock & Moheb M. Nasr
Scientific considerations in the review and approval of generic enoxaparin in the United States
By Daniela Verthelyi, Janet Woodcock & Robert A. Lionberger
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective
By Janet Woodcock & Lawrence J Lesko